FDA
-
-
-
-
-
-
-
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
-
-
-
-
-
-
-
Fortress Biotech unit Cyprium agrees to sell rare disease voucher for $205M
-
-
-
-
-
-
-
FDA accepts resubmitted drug application for rare pediatric disease
-
-
-
-
-
-
-
Journey Medical presents Emrosi clinical trial data at dermatology conference
-
-
-
-
-
-
-
Journey Medical Corporation to Participate in September 2025 Investor Conferences
-
-
-
-
-
-
-
Journey Medical expands Emrosi payer coverage to 65% of commercial lives
-
-
-
-
-
-
-
Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference
-
322,215 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

